Pfizer will buy NextWave Pharma for up to $700M

(AP)—Pfizer said Monday it will buy NextWave Pharmaceuticals Inc., a company that makes a liquid attention deficit hyperactivity disorder drug, in a deal worth as much as $700 million.

The approved NextWave's drug Quillivant XR in September, and the once-per-day drug is expected to be in pharmacies in January.

made a $20 million option payment to Cupertino, California-based NextWave in the second quarter to establish a merger agreement. The company will pay $255 million when the deal closes, and agreed to pay NextWave another $425 million based on sales milestones.

Pfizer said about 9.5 percent of children have received a diagnosis of ADHD at some point, and around 4 percent of adults have the condition.

NextWave is also developing extended release chewable tablets using the same drug. It has an advanced-stage study of the tablets in process, and aims to submit the product for approval next year.

Pfizer expects the deal to close during the fourth quarter, subject to regulatory approval.

Shares of . slipped a penny to $25.75 in premarket trading.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Pfizer drug found with serious side effect

Nov 01, 2006

U.S. pharmaceutical company Pfizer Inc. says clinical trials of its heart medication torcetrapib suggest the drug has a potentially serious side effect.

AT&T goes on spectrum shopping binge

Aug 02, 2012

(AP) — AT&T Inc. has gone on a shopping spree for wireless spectrum, striking three separate deals that should let it increase its capacity for wireless broadband.

Pfizer will buy King Pharmaceuticals for $3.6B

Oct 12, 2010

(AP) -- Pfizer Inc. said Tuesday it will buy a company specializing in pain drugs in a $3.6 billion deal meant to shore up the portfolio of the world's largest drug company.

Citing liver damage, Pfizer withdraws Thelin

Dec 10, 2010

(AP) -- Pfizer Inc. said Friday it is pulling its blood pressure drug Thelin off the market and stopping all clinical trials because the drug can cause fatal liver damage.

Recommended for you

Pyridoxine-doxylamine drug safety data lacking

2 hours ago

(Medical Xpress)—The most commonly prescribed drug for pregnant women suffering from morning sickness in their first trimester does not prevent birth defects even though drug safety data says it does, according to research ...

FDA approves new type 2 diabetes drug

19 hours ago

(HealthDay)—Millions of Americans with type 2 diabetes have a new treatment option with the U.S. Food and Drug Administration's approval Tuesday of a once-weekly injectable drug, Tanzeum.

AAFP provides tips to address patients' vaccine concerns

Apr 14, 2014

(HealthDay)—Physicians remain the biggest influence on whether patients get vaccinated, and must be prepared to address patients' reservations, according to an article published in the March/April issue ...

User comments